Novo Nordisk lifts outlook despite Wegovy oral miss and CagriSema setback
Novo Nordisk raised its full‑year 2025/2026 guidance, now expecting sales and operating profit to decline by no more than 6% at constant exchange rates, an improvement over the prior 4‑12% decline forecast. The company reported second‑quarter adjusted sales of 78.49 billion Danish kroner, up 7% year‑on‑year, and adjusted operating profit of 33.389 billion kroner, up 11%.
Oral Wegovy generated 3.2 billion kroner in Q2, slightly below analysts’ 3.3 billion‑kroner expectation, while the injectable version delivered 19.48 billion kroner. The oral pill has been prescribed over five million times in the United States, with weekly prescriptions exceeding 265 000. A trial of the next‑generation obesity drug CagriSema showed weight‑loss results comparable to Eli Lilly’s tirzepatide but a smaller HbA1c reduction (1.9% versus 2.2%). Despite the upgraded outlook, Novo Nordisk’s shares fell about 5‑6% after the results.
Entities: CagriSema · Eli Lilly · Mike Doustdar · Novo Nordisk · Novo Nordisk A/S · Ozempic · Wegovy (oral)
Claims
What the coverage asserts, and how well corroborated each claim is across sources.
- [● 2 SOURCES] CagriSema trial showed weight‑loss non‑inferior to tirzepatide but HbA1c reduction of 1.9% versus 2.2% for tirzepatide. (077d0247, 42ee9361)
- [● 3 SOURCES] Novo Nordisk's Q2 adjusted sales were 78.49 billion Danish kroner, up 7% YoY. (42ee9361, 2807cdd9, 9df758b9)
- [● 3 SOURCES] Novo Nordisk shares fell about 5‑6% after the earnings release despite the raised outlook. (077d0247, 42ee9361, 7773fce4)
- [● 2 SOURCES] Novo Nordisk raised its full‑year 2025/2026 guidance, expecting sales and operating profit to decline by no more than 6% at constant exchange rates. (077d0247, 42ee9361)
- [● 2 SOURCES] Injectable Wegovy generated 19.48 billion Danish kroner in Q2 revenue. (077d0247, 42ee9361)
- [● 2 SOURCES] Wegovy oral has been prescribed over five million times in the US, with weekly prescriptions exceeding 265 000. (2807cdd9, 9df758b9)
- [● 2 SOURCES] Adjusted operating profit was 33.389 billion Danish kroner, up 11% YoY. (2807cdd9, 9df758b9)
- [● 2 SOURCES] Oral Wegovy sales in Q2 were 3.2 billion Danish kroner, below analysts’ expectation of 3.3 billion kroner. (077d0247, 42ee9361)